Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BeiGene
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
6. Use of Chinese herbal medicines or Chinese patent medicines intended for cancer control within 14 days prior to randomization/enrollment.
7. Presence of active leptomeningeal disease, untreated or uncontrolled brain metastases, or active autoimmune disease.
Note: Additional protocol-defined and sub-study-specific criteria may apply.
You may not be if
2. No prior systemic therapy administered as the primary treatment for metastatic NSCLC. Prior adjuvant or neoadjuvant chemotherapy, definitive chemoradiation, or adjuvant radiotherapy for locally advanced disease is permitted, provided the last dose of chemotherapy and/or radiotherapy occurred at least 6 months prior to randomization/enrollment.
4. At least one measurable lesion, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
1. Diagnosis of mixed small cell lung cancer.
2. Known genomic alterations for which effective targeted therapies are available according to local standard of care, including but not limited to:
3. Participants with nonsquamous NSCLC and unknown EGFR mutation status must undergo local testing. Those found to have EGFR-sensitizing mutations will be excluded.
4. Prior treatment with immune-based therapies that target immune checkpoint pathways, including:
* PD-1 (programmed cell death protein 1) inhibitors
* PD-L1 (programmed death-ligand 1) inhibitors
* PD-L2 (programmed death-ligand 2) inhibitors
* TIGIT (T cell immunoreceptor with Ig and ITIM domains) inhibitors
* LAG-3 (lymphocyte activation gene 3) inhibitors
Clareo Health | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
